OSI Systems, NVE, Biodexa Pharmaceuticals, Virpax Pharmaceuticals, and Clene are the five Nanotechnology stocks to watch today, according to MarketBeat's stock screener tool. Nanotechnology stocks are shares of companies that focus on developing and applying materials, devices, and systems at the nanoscale to create innovative products and technologies. These stocks offer investors exposure to a rapidly evolving field that intersects industries like healthcare, electronics, and energy, potentially driving significant technological and market advancements. These companies had the highest dollar trading volume of any Nanotechnology stocks within the last several days.
OSI Systems (OSIS)
OSI Systems, Inc. designs and manufactures electronic systems and components. It operates in three segments: Security, Healthcare, and Optoelectronics and Manufacturing. The Security segment offers baggage and parcel inspection, cargo and vehicle inspection, hold baggage and people screening, radiation monitoring, explosive and narcotics trace detection systems, and optical inspection systems under the Rapiscan name.
NASDAQ OSIS traded up $1.07 during trading hours on Wednesday, hitting $195.77. 56,837 shares of the company were exchanged, compared to its average volume of 175,417. OSI Systems has a 52-week low of $126.57 and a 52-week high of $220.00. The firm has a market cap of $3.29 billion, a price-to-earnings ratio of 25.20, a PEG ratio of 1.81 and a beta of 1.20. The company has a quick ratio of 1.25, a current ratio of 1.88 and a debt-to-equity ratio of 0.56. The company has a 50 day moving average of $197.63 and a two-hundred day moving average of $172.04.
Read Our Latest Research Report on OSIS
NVE (NVEC)
NVE Corporation develops and sells devices that use spintronics, a nanotechnology that relies on electron spin to acquire, store, and transmit information in the United States and internationally. The company manufactures spintronic products, including sensors and couplers for use in acquiring and transmitting data.
NASDAQ:NVEC traded down $0.75 during mid-day trading on Wednesday, hitting $62.80. The stock had a trading volume of 13,329 shares, compared to its average volume of 21,176. NVE has a twelve month low of $62.03 and a twelve month high of $89.98. The company has a market capitalization of $303.76 million, a PE ratio of 20.26 and a beta of 1.08. The stock has a 50-day simple moving average of $69.34 and a two-hundred day simple moving average of $75.63.
Read Our Latest Research Report on NVEC
Biodexa Pharmaceuticals (BDRX)
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.
Shares of Biodexa Pharmaceuticals stock traded up $0.46 during trading on Wednesday, hitting $1.66. 457,898 shares of the stock were exchanged, compared to its average volume of 499,960. The business's 50-day simple moving average is $3.27. Biodexa Pharmaceuticals has a 12-month low of $1.14 and a 12-month high of $74.00.
Read Our Latest Research Report on BDRX
Virpax Pharmaceuticals (VRPX)
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.
Virpax Pharmaceuticals stock traded up $0.05 during midday trading on Wednesday, reaching $1.33. The company's stock had a trading volume of 170,106 shares, compared to its average volume of 181,266. The business has a 50-day simple moving average of $5.40 and a 200-day simple moving average of $10.36. Virpax Pharmaceuticals has a fifty-two week low of $1.08 and a fifty-two week high of $105.99.
Read Our Latest Research Report on VRPX
Clene (CLNN)
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.
CLNN stock traded up $0.46 during trading on Wednesday, hitting $3.04. 49,490 shares of the company's stock were exchanged, compared to its average volume of 78,384. The stock has a market capitalization of $26.10 million, a price-to-earnings ratio of -0.58 and a beta of 0.27. Clene has a 52-week low of $2.57 and a 52-week high of $9.20. The business has a 50-day moving average price of $4.35 and a two-hundred day moving average price of $4.78.
Read Our Latest Research Report on CLNN
Read More
Before you consider OSI Systems, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OSI Systems wasn't on the list.
While OSI Systems currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
